RED EYE TRIPLE ACTION 1 % — DIN 02518201
POLYETHYLENE GLYCOL 400 : 1 % TETRAHYDROZOLINE HYDROCHLORIDE : 0.05 % · JOHNSON & JOHNSON INC · DROPS · wholesale supply in Canada
Health Canada status: MARKETED
What is RED EYE TRIPLE ACTION?
RED EYE TRIPLE ACTION 1 % contains POLYETHYLENE GLYCOL 400 : 1 % TETRAHYDROZOLINE HYDROCHLORIDE : 0.05 %. It is listed in the Health Canada Drug Product Database under DIN 02518201, held by JOHNSON & JOHNSON INC, supplied as DROPS for OPHTHALMIC administration. Health Canada currently lists it as marketed, status dated 12-Sep-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Is there a generic Tetryzoline, Combinations in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
8 holders have a Canadian DIN containing Tetryzoline, Combinations, across 19 DINs, of which 8 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| JOHNSON & JOHNSON INC | 8 | 4 | RED EYE TRIPLE ACTION, RED EYE WORKPLACE, VISINE COOL, VISINE FOR ALLERGY 3 SYMPTOM RELIEF, VISINE FOR RED EYE COOL, +3 more | Sourceable in Canada |
| JUNO OTC INC | 3 | 3 | 8-SYMPTOM RELIEF, ADVANCED RELIEF EYE DROPS, ALLERGY EYE DROPS | Sourceable in Canada |
| PRESTIGE BRANDS INC | 1 | 1 | CLEAR EYES TRIPLE ACTION RELIEF | Sourceable in Canada |
| KC PHARMACEUTICALS INC | 2 | 0 | ADVANCED RELIEF EYE DROPS, ALLERGY EYE DROPS | No marketed DIN |
| PFIZER CANADA INC., CONSUMER HEALTHCARE DIVISION | 2 | 0 | VISINE A.C. OPHTHALMIC SOL, VISINE EXTRA OPHTHALMIC SOL | No marketed DIN |
| ALCON CANADA INC | 1 | 0 | ALLERGY EYE DROPS | No marketed DIN |
| LABORATOIRES CHARTON LABORATORIES | 1 | 0 | COLLYRIUM EYE DROPS | No marketed DIN |
| WYETH-AYERST CANADA INC. | 1 | 0 | COLLYRIUM EYE DROPS | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 1 % |
|---|---|
| Dosage form | DROPS |
| Route | OPHTHALMIC |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Tetryzoline, Combinations |
|---|---|
| ATC code | S01GA52 |
| AHFS class | 52:32.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02518201 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2518201 |
| Brand name | RED EYE TRIPLE ACTION |
| Generic / active ingredient | POLYETHYLENE GLYCOL 400 : 1 % TETRAHYDROZOLINE HYDROCHLORIDE : 0.05 % |
| Market authorization holder | JOHNSON & JOHNSON INC |
| Health Canada schedule | NON-PRESCRIPTION DRUGS |
| ATC code | S01GA52 |
| ATC anatomical main group | S — Sensory organs |
| ATC therapeutic subgroup | S01GA |
| Current status | MARKETED |
| Status date | 12-Sep-2025 |
| Original market date | 2022-03-15 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
8 of 19 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| 8-SYMPTOM RELIEF | 0.25 % | SOLUTION | JUNO OTC INC | MARKETED | 02448955 |
| ADVANCED RELIEF EYE DROPS | 1 % | SOLUTION | JUNO OTC INC | MARKETED | 02344319 |
| ALLERGY EYE DROPS | 0.05 % | SOLUTION | JUNO OTC INC | MARKETED | 02290596 |
| CLEAR EYES TRIPLE ACTION RELIEF | 0.6 % | SOLUTION | PRESTIGE BRANDS INC | MARKETED | 02301687 |
| RED EYE WORKPLACE | 0.05 % | DROPS | JOHNSON & JOHNSON INC | MARKETED | 02518228 |
| VISINE FOR ALLERGY 3 SYMPTOM RELIEF | 0.25 % | DROPS | JOHNSON & JOHNSON INC | MARKETED | 02144093 |
| VISINE MULTI-SYMPTOM | 0.25 % | DROPS | JOHNSON & JOHNSON INC | MARKETED | 02338602 |
| ADVANCED RELIEF EYE DROPS | 0.1 % | SOLUTION | KC PHARMACEUTICALS INC | APPROVED | 02455293 |
| ALLERGY EYE DROPS | 0.25 % | DROPS | ALCON CANADA INC | CANCELLED POST MARKET | 02248660 |
| ALLERGY EYE DROPS | 0.25 % | SOLUTION | KC PHARMACEUTICALS INC | APPROVED | 02455285 |
2 · Same class — other molecules in ATC S01GA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Tetryzoline, Combinations | 8-SYMPTOM RELIEF · ADVANCED RELIEF EYE DROPS · ALLERGY EYE DROPS · CLEAR EYES TRIPLE ACTION RELIEF · +11 more | 19 | 8 | Yes |
| Naphazoline, Combinations | ALBALON A · ALLERGY EYE DROPS · BLUE COLLYRIUM · CLEAR EYES ACR BY MURINE · +16 more | 21 | 5 | Yes |
| Naphazoline | ALBALON · CLEAR EYES · CLEAR EYES BY MURINE EYE DPS · COLLYRE BLEU LAITER · +12 more | 16 | 2 | Yes |
| Tetryzoline | EYE DROPS · EYE DROPS 0.5MG/ML · ORIGINAL EYE DROPS · R.O.-EYE DROPS · +1 more | 6 | 2 | Yes |
| Phenylephrine, Combinations | DIOROUGE LIQ · OCCU-CAL DROPS · OCCU-CAL LOTION · ODAN-VERNACON · +3 more | 7 | 0 | Not in Canada |
| Oxymetazoline | CLARITIN EYE ALLERGY RELIEF · OCUCLEAR OPH DPS 0.025% · VISINE L.R. OPHTHALMIC SOL 0.025% · VISINE WORKPLACE | 4 | 0 | Not in Canada |
| Phenylephrine | PREFRIN LIQ 0.12% | 1 | 0 | Not in Canada |
| Xylomethazoline, Combinations | OPHTRIVIN A OPHTHALMIC DPS | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC S01G
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| S01GX | Cromoglicic Acid · Emedastine · Ketotifen · Levocabastine · Lodoxamide · +2 more | 35 | 13 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.